Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study - 30/05/24
Abstract |
Aim |
Preclinical studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2is) have a neuroprotective effect. This study compared the risks of carpal tunnel syndrome and carpal tunnel release surgery between new users of SGLT2is and new users of glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Methods |
A retrospective new-user active comparator cohort study with a target trial design was conducted by using the TriNetX platform. Patients with type 2 diabetes mellitus prescribed SGLT2is or GLP-1RAs were identified. Covariates were balanced using propensity score matching to form 2 homogenous treatment groups. Outcomes were the risk of carpal tunnel syndrome and the risk of carpal tunnel release surgery. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using the TriNetX platform.
Results |
The crude cohort included 86,188 and 100,244 patients in the SGLT2is group and GLP-1RAs group, respectively. After matching, each group included 65,464 patients. The SGLT2is group had an average age of 59.6 years, and 46 % were women. The GLP-1RAs group had an average age of 59.5 years, and 45.9 % were women. The incidences of carpal tunnel syndrome (HR: 0.928; 95 % CI: 0.869 to 0.991) and carpal tunnel release surgery (HR: 0.840; 95 % CI: 0.726 to 0.971) were significantly lower in the SGLT2is group than in the GLP-1RAs group.
Conclusion |
In patients with type 2 diabetes mellitus, SGLT2is seem to decrease the risk of carpal tunnel syndrome and the need for carpal tunnel release surgery. Prospective studies are required to confirm our results.
Le texte complet de cet article est disponible en PDF.Keywords : Carpal tunnel release, Carpal tunnel syndrome, Glucagon-like peptide-1 receptor agonists, Sodium-glucose cotransporter 2 inhibitors
Plan
Vol 50 - N° 4
Article 101545- juillet 2024 Retour au numéro
Article précédent
- Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes
- Damien Denimal, Laurence Duvillard, Sarah Béland-Bonenfant, Béatrice Terriat, Jean-Paul Pais-de-Barros, Isabelle Simoneau, Alexia Rouland, Lina Houbachi, Benjamin Bouillet, Bruno Vergès, Jean-Michel Petit
- Menopausal hormone therapy decreases the likelihood of diabetes development in peri‑menopausal individuals with prediabetes
- Yu-Hsiang Shih, Chiao-Yu Yang, Shao-Jing Wang, Chia-Chi Lung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?